Liver problems with Abbott Laboratories Inc.’s discontinued attention deficit drug Cylert and other generic versions are too dangerous for the U.S. market, the Food and Drug Administration said on Monday.

“The agency has concluded that the overall risk of liver toxicity from Cylert and generic pemoline products outweighs the benefits of this drug,” the FDA said in a warning posted on its Web site.

In March, Abbott said it would no longer make the drug due to declining sales, but consumer advocates had argued it was too dangerous to be sold.

 


Comments


View Comments / Leave a Comment

This post currently has 2 comments.
You can read the comments or leave your own thoughts.


    Last reviewed: By John M. Grohol, Psy.D. on 24 Oct 2005
    Published on PsychCentral.com. All rights reserved.

APA Reference
Grohol, J. (2005). Discontinued ADD drug too risky: FDA. Psych Central. Retrieved on November 1, 2014, from http://psychcentral.com/blog/archives/2005/10/24/discontinued-add-drug-too-risky-fda/

 

Recent Comments
  • scrutinize,anylize,contrast: Psychologists, Psychiatrists, MFC’s, LSW,well, they’ll all human. I have had...
  • Paula: ” Things like shooting without looking through the viewfinder” I don’t understand this.
  • Cindy: I have been going through pain for about three years now. I have asked for help with this for three years. I...
  • thatjournalistdork: I agree that the use of “said” does get boring and annoying, but it is proper AP...
  • lisa: I am at a loss,my baby sister who is smart,and loving phoned me one day and starting crying,I hope that I was...
Subscribe to Our Weekly Newsletter


Find a Therapist
Enter ZIP or postal code